Platelet transfusion in AML and autologous stem cell transplantation. Schematic presentation of the randomized platelet transfusion trial and its major outcomes. Patients with acute myeloid leukemia or autologous stem cell transplantation received either the standard dose of 0.5 × 10¹¹ platelets/10 kg b.w., or a higher dose of 1 × 10¹¹ platelets/10 kg b.w. The high dose group had longer periods until the trigger of 20 000 platelets/μL was reached but received numerically more platelets.